share_log

海辰药业(300584.SZ):注射用盐酸兰地洛尔增加规格获得药品补充申请批准通知书

Nanjing Hicin Pharmaceutical (300584.SZ): Approval Notice for Supplementary Drug Application for the increased specification of Landedol Hydrochloride for Injection.

Gelonghui Finance ·  Nov 6, 2024 02:47

On November 6, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) recently received the Approval Notification for the supplementary application of Injection Landlelol Hydrochloride issued by the National Medical Products Administration (referred to as "NMPA"), approving the addition of 150mg specification on top of the approved 50mg specification, and considering it as passing the consistency evaluation.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment